Previous 10 | Next 10 |
Emergent Biosolutions (EBS): Q3 Non-GAAP EPS of $2.19 beats by $0.04; GAAP EPS of $0.73 misses by $1.03.Revenue of $385.2M (+23.5% Y/Y) misses by $53.31M.FY2020 guidance: Total revenues of $1,520M-$1,580M from previous guidance of $1,500M-$1,600M vs consensus of $1.52B ; Adjusted net income o...
Reports strong third quarter and record year to date performance Updates full year guidance — refines revenue ranges and raises profitability ranges GAITHERSBURG, Md., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial result...
Emergent Biosolutions (NYSE:EBS) is scheduled to announce Q3 earnings results on Thursday, November 5th, after market close.The consensus EPS Estimate is $2.15 (+77.7% Y/Y) and the consensus Revenue Estimate is $438.51M (+40.6% Y/Y).Over the last 2 years, EBS has beaten EPS estimates 75% of t...
Emergent BioSolutions has key niche differentiators that strengthen the operating model, with exposure to defence & public health threats. They hold the only FDA approved anthrax vaccine in their portfolio, and ~60% of total revenues are backed by US Government contract agreements...
GAITHERSBURG, Md., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, November 5, 2020 at 5:00 pm (Eastern Time) to discuss the financial results for the third quarter of 2020, recent business developments, revenue guidance for ...
Shares of Emergent BioSolutions (NYSE: EBS) were falling 10.3% as of 11:45 a.m. EDT on Tuesday. The drop came after Johnson & Johnson announced that it had paused its late-stage study of coronavirus vaccine candidate JNJ-78436735 because of an unexplained illness with on...
Gainers: Medigus (MDGS) +84%, Altimmune (ALT) +25%, Enlivex Therapeutics (ENLV) +16%, BiondVax Pharmaceuticals (BVXV) +16%, Aileron Therapeutics (ALRN) +15%.Losers: Gossamer Bio (GOSS) -34%, Avenue Therapeutics (ATXI) -17%, Emergent ...
Gossamer Bio (GOSS) -32% after two studies in GB001, Phase 2B LEDA trial in eosinophilic asthma and Phase 2 TITAN trial in chronic rhinosinusitis, failed to meet the primary endpoints.Wah Fu Education (WAFU) -23%.Hexindai (HX) -20%.Medley Management (MDLY) -19%.I...
Catalent produces vaccines developed by biotech companies both in the U.S. and in Europe. Its results have been impacted by COVID-19, but the company has some strong growth drivers and margins are in the double digits. However, there are high capital expenses and operational costs...
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Eyes On Stimulus Developments AgainInvestors are still largely focused on new twists and turns with stimulus efforts in the U.S. Last night, President Dona...
News, Short Squeeze, Breakout and More Instantly...
Emergent Biosolutions Inc. Company Name:
EBS Stock Symbol:
NYSE Market:
Emergent Biosolutions Inc. Website:
New video and radio segments raise awareness of a potentially life-saving, three-step method that anyone can use to respond in a suspected opioid poisoning GAITHERSBURG, Md., July 24, 2024 (GLOBE NEWSWIRE) -- Today, Emergent BioSolutions Inc. (NYSE: EBS) announced the launch of a new opio...
GAITHERSBURG, Md., July 23, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Tuesday, August 6, 2024, at 5:00 pm eastern time to discuss the financial results for the second quarter 2024, key business updates, revenue guidance for the third quarter of...
The extension to a four-year shelf-life helps improve naloxone access as communities continue to grapple with the growing opioid epidemic; product with the extended shelf life has officially begun shipping WINNIPEG, Manitoba, July 22, 2024 (GLOBE NEWSWIRE) -- Today, Emergent BioSolution...